This is a news story, published by CNBC, that relates primarily to Novo Nordisk's news.
For more Novo Nordisk's news, you can click here:
more Novo Nordisk's newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
blockbuster diabetes drug Ozempic. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest diabetes care news, insulin news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
diabetes treatmentCNBC
•86% Informative
A month 's supply of the treatment could be made for an estimated 89 cents to $ 4.73 , figures that include a profit margin.
The study raises more questions about the hefty price tag of the top-selling diabetes treatment.
Novo Nordisk's list price for a monthly package of Ozempic is $ 935.77 before insurance and other rebates.
VR Score
89
Informative language
89
Neutral language
69
Article tone
formal
Language
English
Language complexity
48
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links